Questioning How to Define the "Ultra-High-Risk" Subgroup of Neuroblastoma Patients.

Neuroblastic tumours exhibit heterogeneity, which results in different therapeutic outcomes. Neuroblastoma is categorized into three major risk groups (low, intermediate, high risk). Recent identification of new genes raised the possibility of new biomarkers to identify sub-risk groups. In this retrospective cross-sectional study, we aimed to assess new biomarkers defining the ultra-high-risk subgroup within the high-risk group that differ in clinical situation with very bad prognosis. Twenty-five low- and 29 high-risk groups of patients were analysed for their expression of ALK, ATRX, HIF1a, HIF2a (EPAS), H2AFX, and ETV5 genes at the RNA level. Immunohistochemistry was performed to confirm the protein expression level of ALK. The risk group of patients was determined according to the International Neuroblastoma Risk Group Stratification System. Spearman correlation analysis and Mann-Whitney-U nonparametric test were used to assess the importance of expression levels among the groups. P < 0.05 was considered as significant. Sensitivity of the results was checked by ROC curve analysis. All analysed genes were found to be highly expressed in the high-risk group compared to the low-risk group, except for ETV5. When the ultra-high-risk and highrisk groups were compared, ALK was found to be highly expressed in the ultra-high-risk group. Our results show that ALK may be a candidate gene whose mRNA expression levels can distinguish the ultrahigh- risk subgroup of patients in the high-risk group of patients with non-familial neuroblastoma.

[1]  N. Ratner,et al.  The “neuro” of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder , 2016, Annals of neurology.

[2]  M. Fischer,et al.  Telomere maintenance is pivotal for high-risk neuroblastoma , 2016, Cell cycle.

[3]  G. Melino,et al.  Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis , 2015, Cell Death and Disease.

[4]  D. Zwijnenburg,et al.  Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .

[5]  Simon C Watkins,et al.  Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.

[6]  G. Tonini,et al.  Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma Group , 2015, Pediatric blood & cancer.

[7]  S. Påhlman,et al.  Differential regulation of HIF-1α and HIF-2α in neuroblastoma: Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome. , 2015, Biochemical and biophysical research communications.

[8]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[9]  J. Christensen,et al.  Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells , 2012, Oncogene.

[10]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[11]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[12]  R. George,et al.  Emerging importance of ALK in neuroblastoma. , 2011, Seminars in cancer biology.

[13]  V. Firlej,et al.  Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription , 2008, Journal of Cell Science.

[14]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[15]  H. Carén,et al.  High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene , 2008, BMC Genomics.

[16]  J. Maris,et al.  CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas , 2008, Journal of the National Cancer Institute.

[17]  P. Kogner,et al.  Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24 , 1999, British Journal of Cancer.

[18]  D. Stram,et al.  Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas , 1999, Oncogene.

[19]  H. Caron,et al.  Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. , 1995, Medical and pediatric oncology.

[20]  H. B. Marsden,et al.  Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. , 1984, Journal of the National Cancer Institute.